5-Amino-1MQ
5-amino-1MQ · 1MQ · 5-Amino-1-methylquinolinium
Small-molecule NNMT inhibitor investigated for fat loss and metabolic research; limited human data.
Key takeaways
- Small-molecule NNMT inhibitor — not actually a peptide, despite appearing in peptide vendor catalogs.
- All evidence is preclinical: mouse studies show reduced fat mass and improved insulin sensitivity.
- No human trials, no approved use, no established human dose or safety profile.
- Plotter half-life (roughly 12 hours) and bioavailability are estimates, not measured human values.
Reported dosing protocols
Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.
| Use case | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Fat loss (community) | 50 mg | Oral | 1–2× daily | 4–8 weeks |
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 12 hours
- Bioavailability
- 50%
- Typical dose
- 25–100 mg
Frequently asked questions
Is 5-amino-1MQ a peptide?
No. It's a small molecule (a methylquinolinium derivative) sold alongside peptides by research-chemical vendors, which is where the confusion comes from. Community use is oral rather than injected.
Does 5-amino-1MQ work for fat loss?
In mice, yes: NNMT inhibition reversed high-fat-diet-induced obesity in a 2018 study. In humans, nobody knows. There are no clinical trials at all, so any reported human effect is anecdote.
Is 5-amino-1MQ safe?
Unknown. No human safety data exists, and long-term NNMT inhibition touches NAD+ and methylation pathways that matter broadly. Short mouse studies can't answer chronic human safety questions.
References
- Estimated (preclinical) — NNMT inhibitor; human PK not established.
- Neelakantan et al., Biochem Pharmacol 2018 — NNMT inhibitors reverse obesity in mice — The core preclinical study behind 5-amino-1MQ fat-loss claims.
Related compounds
AICAR
AMPK-activating nucleotide studied as an exercise mimetic for endurance and metabolic research.
SLU-PP-332
Estrogen-related receptor agonism ("exercise mimetic") researched for metabolic and endurance effects.
Semaglutide Injection (Ozempic/Wegovy)
Long-acting GLP-1 receptor agonist for type 2 diabetes and weight loss; weekly injection.
Comments
Loading comments…